Article

Detection of dermicidin-derived peptides in sweat by ProteinChip (R) Technology

Section for Transplantation Immunology and Immunohaematology, University of Tuebingen, Waldhoernlestr. 22, 72072, Tuebingen, Germany.
Journal of Immunological Methods (Impact Factor: 2.01). 01/2003; 270(1):53-62. DOI: 10.1016/S0022-1759(02)00229-6
Source: PubMed

ABSTRACT Recently, a novel antimicrobial peptide DCD-1, derived from the Dermcidin (DCD) gene and secreted by sweat glands, has been described by Schittek et al. [Nat. Immunol. 2 (2001) 1133.]. Here we describe the application of the surface-enhanced laser desorption/ionisation (SELDI) technology for the detection of DCD-1 and other dermcidin-derived peptides directly from microlitre amounts of human sweat. The advantages of the technique are as follows: (a) it can be carried out with ease and rapidity; (b) multiple samples can be processed simultaneously; (c) prior purification is not required; and (d) only a limited sample volume is necessary for both protein profiling and semiquantitation. Profiling of human sweat from various donors revealed that in addition to DCD-1, other DCD-derived peptide species were also present in significant quantities. Four of five identified peptides were DCD-1 related, while the fifth corresponded to a portion of the DCD protein outside the DCD-1 core. This provides clues as to how the novel protein is processed to its active form, though further work remains to elucidate this fully. Thus, we have demonstrated the applicability of such technology to the detection of DCD-1 and for the protein profiling of sweat in general. Such studies could reveal valuable new biomarkers for diagnosis and treatment of skin and sweat gland disorders.

Download full-text

Full-text

Available from: Claus Garbe, Sep 01, 2015
0 Followers
 · 
169 Views
 · 
167 Downloads
  • Source
    • "Y-P30 triggers signaling at the level of the neuronal membrane and the antimicrobial dermcidin peptides kills bacteria by forming large ion pores in the cell wall [36]. The nature of the secreted peptide species and the mechanism of processing of the precursor are currently only known in sweat glands for the dermcidin [37,38]. We therefore aimed to understand how Y-P30 is secreted from cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background The survival promoting peptide Y-P30 has a variety of neuritogenic and neuroprotective effects in vitro and in vivo. In previous work we reported the expression of Y-P30/dermcidin in maternal peripheral blood mononuclear cells (PBMCs) and the transport of the protein to the fetal brain. In this study we analyzed hormonal regulation of Y-P30 in human immune cells and expression of Y-P30 in the placenta. We further studied the stability and secretion of the Y-P30 peptide. Results We found indications that Y-P30 might be produced in human placenta. The Y-P30 mRNA was rarely found in isolated human PBMCs and alpha-feto-protein, human chorionic gonadotropin as well as estradiol combined with progesterone could not induce Y-P30 expression. Y-P30 was found to be extraordinarily stable; therefore, contamination with the peptide and the Y-P30/Dermcidin precursor mRNA is a serious concern in experiments looking at the expression of Y-P30/Dermcidin. In cultured cell lines and primary neurons we found that Y-P30 could be released, but neuronal uptake of Y-P30 was not observed. Conclusions Our data suggest that a source of Y-P30 apart from eccrine glands might be the placenta. The peptide can be secreted together with the signaling peptide and it might reach the fetal brain where it can exert its neuritogenic functions by binding to neuronal membranes.
    BMC Research Notes 06/2014; 7(1):400. DOI:10.1186/1756-0500-7-400
  • Source
    • "To overcome this major pitfall, an alternative approach for quantitative analysis employing internal standards can be applied. Reference peptides such as insulin can be spiked into the samples and used for normalizing of the respective spectra [35]. Studies using MALDI-TOF MS for absolute peptide quantification are quite rare and normally based on the use of heavy isotope internal standards [36] [37] [38]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The discovery of novel biomarkers by means of advanced detection tools based on proteomic analysis technologies necessitates the development of improved diagnostic methods for application in clinical routine. On the basis of three different application examples, this review presents the limitations of conventional routine diagnostic assays and illustrates the advantages of immunoaffinity enrichment combined with MALDI-TOF MS. Applying this approach increases the specificity of the analysis supporting a better diagnostic recognition, sensitivity, and differentiation of certain diseases. The use of MALDI-TOF MS as detection method facilitates the identification of modified peptides and proteins providing additional information. Further, employing respective internal standard peptides allows for relative and absolute quantitation which is mandatory in the clinical context. Although MALDI-TOF MS is not yet established for clinical routine diagnostics this technology has a high potential for improvement of clinical diagnostics and monitoring therapeutic efficacy.
    Proteomics 03/2009; 9(6):1442-50. DOI:10.1002/pmic.200800616 · 3.97 Impact Factor
  • Source
    • "Although it is not clear how these polypeptides are produced from the entire DCD protein, it is likely that differential proteolysis is responsible for the production of the different DCD peptides. Four different peptides have been identified in sweat, and all of these peptides appear to be proteolytic products (Flad et al. 2002). However, the specific proteases involved in differential proteolysis remain to be determined. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dermcidin (DCD), an antimicrobial peptide that is secreted by sweat glands, is reportedly a human homolog of mouse proteolysis-inducing factor. This study was conducted to investigate the effect of DCD on body fat mobilization. The expression level of DCD in the livers of Ad-DCD-injected mice was higher than in those of Ad-beta-galactosidase (Ad-beta-gal)-injected mice 7 days after injection. In addition, injection with the Ad-DCD virus led to decreased body weight and epididymal fat mass when compared with controls. The plasma triglyceride level was decreased, whereas the free fatty acid and glycerol levels were increased in the Ad-DCD-injected group. Epididymal adipose tissues obtained from Ad-DCD-injected mice consisted of smaller adipocytes than tissues obtained from Ad-beta-gal-injected mice. The gene expression profiles revealed an upregulation of hormone-sensitive lipase and adipose fatty acid-binding protein, both of which are involved in adipocyte lipolysis, in Ad-DCD-injected mice, and this lipolytic effect of DCD paralleled the increase of circulating tumor necrosis factor-alpha (TNF-alpha) level that was observed. The perilipin levels in adipose tissue were decreased in Ad-DCD-injected mice when compared with those of the control mice. Taken together, these results suggest that DCD-mediated body fat reduction might occur as a result of TNF-alpha-induced downregulation of perilipin in adipose tissue.
    Journal of Endocrinology 08/2008; 198(1):111-8. DOI:10.1677/JOE-07-0599 · 3.59 Impact Factor
Show more